Johnson and Johnson reports strong gains in 1996
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's professional sales rose 19.8% to $8,068 million in 1996, reflecting the company's acquisition of Cordis and the continued growth of its existing interventional cardiology product range. "We are particularly pleased to have created, in a very short period of time, a major cardiovascular business through the successful acquisition and integration of Cordis with our Interventional Systems business and its highly successful Palmaz-Schatz stent," said CEO Ralph Larsen.